Feedback
The current prices are delayed. Login to see live prices.
Lincoln Pharmaceuticals Ltd.
(LINCOLN)
501234567896012345678970123456789.1012345678900123456789
+2.65 (+0.47%)
Updated 15:51 21/02 IST
Add
1D
5D
1M
3M
1Y
5Y
MAX
Today's low
₹556.00
Today's high
₹582.75
52 week low
₹300
52 week high
₹979.5
Open
₹563
Prev Close
₹564.45
Volume (shares)
78,629
Total Trading Value
4.44 Cr
Technicals
SMA
Value
Signal
12-SMA
633.98
Bearish
20-SMA
661.31
Bearish
50-SMA
746.43
Bearish
100-SMA
721.72
Bearish
200-SMA
686.97
Bearish
Discussions
• Feb 16 5:24 AM
Lincoln Pharma - Quarterly Results
Earnings Update...read more
• Feb 13 7:05 PM
Lincoln Pharmaceuticals Reports Q3 FY25 Financial Results
• For Q3 FY25, Lincoln Pharmaceuticals reported a net profit of Rs. ...read more
• Feb 13 6:33 PM
Lincoln Pharmaceuticals Reports Q3 and Nine Months Financial Results for FY25
• Lincoln Pharmaceuticals reported a revenue of Rs. 455.05 crore for...read more
• Feb 12 12:30 AM
• Feb 5 5:15 PM
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Qu...read more
Load More Posts
Frequently Asked Questions (FAQs)
What is the Share Price of Lincoln Pharmaceuticals Ltd. ?
The share prices are volatile and fluctuate throughout the trading hours. The share price of Lincoln Pharmaceuticals Ltd. is Rs 564.45 as of 21 February 2025.
What is the Market Capitalization of Lincoln Pharmaceuticals Ltd. ?
The current market cap of Lincoln Pharmaceuticals Ltd. is undefined Market capitalisation is calculated by multiplying the current share price with the total number of shares.
What are the PE and PB ratios of Lincoln Pharmaceuticals Ltd.?
Lincoln Pharmaceuticals Ltd. has a price-to-earnings (PE) ratio of undefined and a price-to-book (PB) ratio of undefined.
What is the 52-week high/low of Lincoln Pharmaceuticals Ltd.?
The 52-week high of Lincoln Pharmaceuticals Ltd. is Rs 979.5 and the 52-week low is Rs 300
Join 10,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Create your account on Frontpage
FrontPage © 2025